Skip to Main Content

Author Details

Ryan Dittamore
Decipher Biosciences Inc.
2013
35
23
PMIDPaper TitleJournal TitlePublished Year
32417369Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study.Eur Urol Oncol2021
34518634Author Correction: Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis.NPJ Precis Oncol2021
34385567Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis.NPJ Precis Oncol2021
34129855Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial.Ann Oncol2021
33262136Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer.Clin Cancer Res2021
32127465SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy.Mol Cancer Ther2020
32017048Minimum Technical Data Elements for Liquid Biopsy Data Submitted to Public Databases.Clin Pharmacol Ther2020
31705765Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.Genes Chromosomes Cancer2020
31648903Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate Cancer.Eur Urol2020
32816908Morphology-Predicted Large-Scale Transition Number in Circulating Tumor Cells Identifies a Chromosomal Instability Biomarker Associated with Poor Outcome in Castration-Resistant Prostate Cancer.Cancer Res2020
32341031Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer.Clin Cancer Res2020
32165065Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.Eur Urol2020
30703186Improving the Nuclear-Localized Androgen Receptor Splice Variant 7 Test-In Reply.JAMA Oncol2019
32832835Circulating Tumor Cells as a Predictor of Treatment Response in Clinically Localized Prostate Cancer.JCO Precis Oncol2019
30894499Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.Sci Transl Med2019
30865549Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.J Clin Oncol2019
30514390Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.J Immunother Cancer2018
29983880Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer.Oncotarget2018
29955787Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer.JAMA Oncol2018
29978216Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.JAMA Oncol2018
27539393Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.BJU Int2017
28187516Collaborating to Compete: Blood Profiling Atlas in Cancer (BloodPAC) Consortium.Clin Pharmacol Ther2017
28446544Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival.Cancer Epidemiol Biomarkers Prev2017
28957377Androgen receptor expression on circulating tumor cells in metastatic breast cancer.PLoS One2017
28819021Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer.Cancer Res2017
28655452High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer.Clin Genitourin Cancer2017
27979426Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.Eur Urol2017
27262168Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.JAMA Oncol2016
26671992The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer.Clin Cancer Res2016
27851748Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis.PLoS One2016
27618023Circulating Tumor Cells (CTC) and Cell-Free DNA (cfDNA) Workshop 2016: Scientific Opportunities and Logistics for Cancer Clinical Trial Incorporation.Int J Mol Sci2016
27658492Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.BMC Cancer2016
28936239Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization.J Circ Biomark2015
28936240Detection and Characterization of Circulating Tumour Cells from Frozen Peripheral Blood Mononuclear Cells.J Circ Biomark2015
23653096ERG overexpression and PTEN status predict capsular penetration in prostate carcinoma.Prostate2013
  • 1 - 35 of 35

Recommended Authors

Sinja Taavitsainen
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 2018
Number of shared co-authors 8
Cameron Herberts
University of British Columbia
Career Start Year 2018
Number of shared co-authors 17
Minke Smits
Radboud University Medical Center
Career Start Year 2017
Number of shared co-authors 0
Wei Yuan
The Institute for Cancer Research
Career Start Year 2015
Number of shared co-authors 15
Lisanne F van Dessel
Erasmus MC Cancer Institute
Career Start Year 2015
Number of shared co-authors 0
Pedro Isaacsson Velho
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Career Start Year 2013
Number of shared co-authors 6
Matti Annala
University of British Columbia
Career Start Year 2011
Number of shared co-authors 21
Adam G Sowalsky
National Cancer Institute
Career Start Year 2010
Number of shared co-authors 12
Alec Paschalis
The Institute for Cancer Research
Career Start Year 2009
Number of shared co-authors 5
Mohammed Alshalalfa
University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center
Career Start Year 2009
Number of shared co-authors 20
Susana Miranda
The Institute of Cancer Research
Career Start Year 2008
Number of shared co-authors 19
Arun A Azad
Peter MacCallum Cancer Centre
Career Start Year 2007
Number of shared co-authors 8
Mark M Pomerantz
Dana-Farber Cancer Institute
Career Start Year 2007
Number of shared co-authors 14
Alan H Bryce
Mayo Clinic
Career Start Year 2006
Number of shared co-authors 15
Alok K Tewari
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 5
Niven Mehra
Radboud university medical center
Career Start Year 2004
Number of shared co-authors 20
Adam Foye
University of California San Francisco
Career Start Year 2003
Number of shared co-authors 18
Adam Sharp
The Institute for Cancer Research
Career Start Year 2003
Number of shared co-authors 15
Ashley E Ross
Northwestern University
Career Start Year 2003
Number of shared co-authors 22
Heather H Cheng
Fred Hutchinson Cancer Center, University of Washington
Career Start Year 2002
Number of shared co-authors 34
Wassim Abida
Memorial Sloan Kettering Cancer Center
Career Start Year 2002
Number of shared co-authors 33
Mark C Markowski
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Career Start Year 2001
Number of shared co-authors 9
Ilsa Coleman
Fred Hutchinson Cancer Center
Career Start Year 2001
Number of shared co-authors 24
Eleni Efstathiou
Houston Methodist Cancer Center
Career Start Year 2000
Number of shared co-authors 19
David T Miyamoto
Massachusetts General Hospital
Career Start Year 2000
Number of shared co-authors 7
Joshua M Lang
19University of Wisconsin Carbone Cancer Center.
Career Start Year 2000
Number of shared co-authors 24
Jie-Fu Chen
Memorial Sloan Kettering Cancer Center
Career Start Year 1999
Number of shared co-authors 4
Martijn P Lolkema
Erasmus MC Cancer Institute
Career Start Year 1999
Number of shared co-authors 9
Evan Y Yu
University of Washington and Fred Hutchinson Cancer Research Center
Career Start Year 1997
Number of shared co-authors 40
Bruce Montgomery
Fred Hutchinson Cancer Center, University of Washington
Career Start Year 1990
Number of shared co-authors 33

Collaborators

Howard I Scher
Memorial Sloan Kettering Cancer Center
Co-authored papers 12
Scott A Tomlins
Rogel Cancer Center, University of Michigan Medical School ann arbor
Co-authored papers 5
Himisha Beltran
Dana-Farber Cancer Institute
Co-authored papers 5
David M Nanus
Sandra and Edward Meyer Cancer Center
Co-authored papers 5
Michael Sigouros
Caryl and Israel Englander Institute for Precision Medicine
Co-authored papers 4
Juan Miguel Mosquera
Caryl and Israel Englander Institute for Precision Medicine
Co-authored papers 4
Scott T Tagawa
Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital
Co-authored papers 4
Gerhardt Attard
The Institute of Cancer Research
Co-authored papers 3
Daniel H Hovelson
Michigan Center for Translational Pathology, University of Michigan ann arbor
Co-authored papers 3
Elai Davicioni
Veracyte Inc.
Co-authored papers 3
Melanie Hullings
University of Texas Southwestern Medical Center
Co-authored papers 3
James Hicks
Michelson Center for Convergent Bioscience, University of Southern California
Co-authored papers 3
Anand Kolatkar
Michelson Center for Convergent Bioscience, University of Southern California
Co-authored papers 3
Emmanuel S Antonarakis
The Sidney Kimmel Cancer Comprehensive Cancer Center at Johns Hopkins
Co-authored papers 3
Peter Kuhn
University of Tubingen
Co-authored papers 3
Edwin M Posadas
Cedars-Sinai Medical Center
Co-authored papers 2
Muneesh Tewari
University of Michigan ann arbor
Co-authored papers 2
Hsian-Rong Tseng
Jonsson Comprehensive Cancer Center, University of California los angeles
Co-authored papers 2
James Godsey
Illumina Inc.
Co-authored papers 2
Gideon M Blumenthal
Oncology Center of Excellence
Co-authored papers 2
Yang Liu
Veracyte inc.
Co-authored papers 2
Olivier Elemento
Meyer Cancer Center
Co-authored papers 2
David A Eberhard
Lineberger Comprehensive Cancer Center, University of North Carolina
Co-authored papers 2
Allison Welsh
Exact Sciences Corporation
Co-authored papers 2
Arne Gruen
Charite-University Hospital Berlin
Co-authored papers 2
Loredana Puca
Sandra and Edward Meyer Cancer Center
Co-authored papers 2
Robert L Grossman
University of Chicago
Co-authored papers 2
AmirAli Talasaz
University of California San Diego Moores Cancer Center
Co-authored papers 2
Phillip G Febbo
Illumina Inc.
Co-authored papers 2
Jake Vinson
Prostate Cancer Clinical Trials Consortium (PCCTC)
Co-authored papers 2
Release 1.2